Hybrid and decentralized clinical trials (DCTs) are fast becoming the norm, but they often involve multiple vendors and service providers, presenting sponsors and CROs with new considerations on the logistics of study conduct. By leveraging the expertise of their vendors, sponsors and contract research organizations (CROs) can avoid common pitfalls that can contribute to inefficiencies, safety concerns, and increased costs.
Read the Drug Discovery World article by Stephanie Larimer, Q2 Solutions, Decentralized Trials Solutions Manager and Tom Brazier, mdgroup, Decentralized Clinical Solutions Director, as they shared their insights and opportunities for decentralized clinical trials and how common pitfalls can be avoided through communications and streamlined working.
Read the article
Visium spatial profiling is a next-generation sequencing method that enables the analysis of cellular relationships by combining transcriptomics with histological techniques. It has advantages over...
Experience the Labmatrix platform in a sandboxed environment with this expert led training session.
Our client speaks about collaboration with Biofortis team, efficiency of reports created and enhanced client relations.